<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01290510</url>
  </required_header>
  <id_info>
    <org_study_id>TCHY106Tendon-2010-08</org_study_id>
    <nct_id>NCT01290510</nct_id>
  </id_info>
  <brief_title>Hyaluronan in the Treatment of Painful Tendinopathy</brief_title>
  <official_title>Hyaluronan in the Treatment of Painful Tendinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TRB Chemedica AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TRB Chemedica AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy and safety of TCHY106 (2%&#xD;
      hyaluronan) in the treatment of painful tendinopathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Visual Analogue Scale of pain (VAS; 100 millimetres (mm)) on day 35</measure>
    <time_frame>Baseline and Day 35</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale of pain (VAS; 100 mm) on day 7</measure>
    <time_frame>On Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale of pain (VAS; 100 mm) on day 90</measure>
    <time_frame>On Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters at baseline</measure>
    <time_frame>At baseline</time_frame>
    <description>Redness&#xD;
Warmth&#xD;
Swelling&#xD;
Tenderness on palpation&#xD;
Crepitus on motion&#xD;
Accumulation of tissue fluid&#xD;
Measured by 5-point scale, ranking from 'none' to 'extreme' intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters on day 7</measure>
    <time_frame>On Day 7</time_frame>
    <description>Redness&#xD;
Warmth&#xD;
Swelling&#xD;
Tenderness on palpation&#xD;
Crepitus on motion&#xD;
Accumulation of tissue fluid&#xD;
Measured by 5-point scale, ranking from 'none' to 'extreme' intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters on day 35</measure>
    <time_frame>On Day 35</time_frame>
    <description>Redness&#xD;
Warmth&#xD;
Swelling&#xD;
Tenderness on palpation&#xD;
Crepitus on motion&#xD;
Accumulation of tissue fluid&#xD;
Measured by 5-point scale, ranking from 'none' to 'extreme' intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters on day 90</measure>
    <time_frame>On Day 90</time_frame>
    <description>Redness&#xD;
Warmth&#xD;
Swelling&#xD;
Tenderness on palpation&#xD;
Crepitus on motion&#xD;
Accumulation of tissue fluid&#xD;
Measured by 5-point scale, ranking from 'none' to 'extreme' intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire at baseline</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire on day 7</measure>
    <time_frame>On Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire on day 35</measure>
    <time_frame>On Day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire on day 90</measure>
    <time_frame>On Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's and investigator's global evaluation of study-relevant tendon complaints on day 7</measure>
    <time_frame>On Day 7</time_frame>
    <description>Measured by Clinical Global Impression (CGI) 7-point scale, ranking from 'very much improved' to 'very much worse' condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's and investigator's global evaluation of study-relevant tendon complaints on day 35</measure>
    <time_frame>On Day 35</time_frame>
    <description>Measured by Clinical Global Impression (CGI) 7-point scale, ranking from 'very much improved' to 'very much worse' condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's and investigator's global evaluation of study-relevant tendon complaints on day 90</measure>
    <time_frame>On Day 90</time_frame>
    <description>Measured by Clinical Global Impression (CGI) 7-point scale, ranking from 'very much improved' to 'very much worse' condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of test product-related Adverse Events</measure>
    <time_frame>Up to Day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Tendinopathy</condition>
  <arm_group>
    <arm_group_label>hyaluronic acid sodium salt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hyaluronic acid sodium salt</intervention_name>
    <description>Two injections of 2 % (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval.</description>
    <arm_group_label>hyaluronic acid sodium salt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients between 18 and 75 years of age and good general health&#xD;
             condition.&#xD;
&#xD;
          -  Signed written informed consent.&#xD;
&#xD;
          -  Painful tendinopathy since ≥ 6 weeks.&#xD;
&#xD;
          -  Pain according to Visual Analogue Scale (VAS; 100 millimetres (mm)) ≥ 40 mm.&#xD;
&#xD;
          -  Ensured compliance of subjects for study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with any investigational product within 4 weeks prior to study entry.&#xD;
&#xD;
          -  Patients with known hypersensitivity to the products (that is active compound and&#xD;
             excipients) or any component or procedure used in the study.&#xD;
&#xD;
          -  Severe intercurrent illness (for example: uncontrolled diabetes mellitus, peripheral&#xD;
             neuropathy), which in the opinion of the investigator, may put the patient at risk&#xD;
             when participating in the study, or affect the patient's ability to take part in the&#xD;
             study.&#xD;
&#xD;
          -  Concomitant disease at study relevant site influencing study evaluation.&#xD;
&#xD;
          -  List of diseases or characteristics judged by the investigator to be incompatible with&#xD;
             the assessments and/or procedures for the study evaluation.&#xD;
&#xD;
          -  List of concomitant medications not allowed.&#xD;
&#xD;
          -  Patients treated with: systemic and/or local steroids within the last 4 weeks,&#xD;
             immunosuppressive drugs within the last 3 months, repeated use of non-steroidal&#xD;
             anti-inflammatory drugs (NSAIDs) within the last week or occasional use within 24&#xD;
             hours.&#xD;
&#xD;
          -  Recent history of drug and/or alcohol abuse (within the last 6 months).&#xD;
&#xD;
          -  List of contra-indications to the treatment.&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  Fertile women who do not accept the consistent and correct use of highly effective&#xD;
             methods of birth control defined as implants, injectables, combined oral&#xD;
             contraceptives, intrauterine devices (IUDs), sexual abstinence or vasectomised partner&#xD;
             during the treatment period and the first 4 weeks follow-up period.&#xD;
&#xD;
          -  Subjects unable to understand informed consent or having a high probability of non&#xD;
             compliance to the study procedures and or non completion of the study according to&#xD;
             investigator's judgement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nils Lynen, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orthopädische Gemeinschaftspraxis Elisengalerie, Aachen (Germany)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zentrum für Orthopädie und Sportmedizin München</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopädische Gemeinschaftspraxis Elisengalerie</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52062</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>January 28, 2011</study_first_submitted>
  <study_first_submitted_qc>February 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2011</study_first_posted>
  <last_update_submitted>September 21, 2011</last_update_submitted>
  <last_update_submitted_qc>September 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tendinopathy</keyword>
  <keyword>hyaluronan</keyword>
  <keyword>tendon</keyword>
  <keyword>hyaluronic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tendinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

